Cargando…

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort

OBJECTIVE: To describe SLE disease activity patterns in the Hopkins Lupus Cohort. METHODS: Disease activity was studied in 1886 patients followed-up for 1–28 years. Disease activity patterns were defined using (1) Physician Global Assessment (PGA) and (2) modified SLE Disease Activity Index (M-SLEDA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Györi, Noémi, Giannakou, Ioanna, Chatzidionysiou, Katerina, Magder, Laurence, van Vollenhoven, Ronald F, Petri, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307372/ https://www.ncbi.nlm.nih.gov/pubmed/28243457 http://dx.doi.org/10.1136/lupus-2016-000192

Ejemplares similares

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
por: Davidson, Julie E, et al.
Publicado: (2018)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?
por: Magder, Laurence S, et al.
Publicado: (2023)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
por: Nived, Ola, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2017)

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres
por: Tani, Chiara, et al.
Publicado: (2018)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i49lnsnt4205qd3p02hspflnl9